Other notable side effects include injection site reactions (redness, itching, or swelling at the injection site), fatigue, and hypoglycemia, particularly when tirzepatide is used in combination with insulin or sulfonylureas
The microdosing schedule may be prescribed as follows: Weeks 14: 1.0 mg once weekly Weeks 58: 1.5 mg once weekly Weeks 912: 2.0 mg once weekly Week 13 and beyond: Transition to the standard 2.5 mg dose, then proceed with the standard escalation plan
Many suppliers offer bulk purchasing options for patients requiring long-term treatment
Your body, especially your brain, relies on a steady supply of glucose for energy
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes